Furthermore, considering that HA dihydrochloride has been used as an adjuvant to IL-2 immunotherapy with proven clinical benefit in acute myeloid leukemia [50,51], it is important to point out that the GS-HA nanoformulation produced comparable antitumoral and antiangiogenic responses at the administered doses when compared to the chemotherapeutic-loaded micelles, highlighting the feasible therapeutic exploitation of this biogenic amine. The gene discussed is IL2; the disease is acute myeloid leukemia.